About a third of them do not achieve adequate relief from traditional antidepressant medications and psychotherapy. The Pine ...

To treat depression, the tech magnate has said he'd rather use ketamine, a dissociative anesthetic, than traditional antidepressants.

Neumora Therapeutics Inc.’s shares plummeted after the company’s experimental drug failed to show a benefit in a final-stage ...

The well-funded biotech lost most of its value after its drug flunked a late-stage trial. One analyst described the results ...

Key Takeaways Neumora Therapeutics reported its experimental depression drug didn't meet expectations, and shares plunged.The ...

Those on the extreme end of the depression spectrum face symptoms that impact their daily activities too and not just their ...

After six weeks, both the treatment group and the placebo group experienced an average 12.5-point reduction on the Montgomery-Åsberg Depression Rating Scale (MADRS). The drug also fell short in i ...

Ketamine, a hallucinogenic drug approved as an anesthetic, has been used to treat adults with depression, PTSD and other conditions, and studied in youth with depression.

Mebufotenin is under clinical development by GH Research and currently in Phase I for Unspecified Psychiatric Disorders.

Neumora Therapeutics, Inc. (NASDAQ:NMRA) stock traded lower after the company released data from the Phase 3 KOASTAL-1 Study ...